A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Genentech
  • Most Recent Events

    • 18 Jul 2012 Results published in Cancer.
    • 18 Jul 2012 Primary endpoint 'Progression-free-survival-duration' has not been met according to results published in Cancer.
    • 18 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top